PharmGKB. Stanford University. Available from: https://www.pharmgkb.org/. [Last accessed: December16, 2024].
2.
Ingelman-SundbergM. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med, 2001; 250(3):186–200; doi: 10.1046/j.1365-2796.2001.00879
3.
Maitland-Van Der ZeeAH, De BoerA, LeufkensHG. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol, 2000; 410(2–3):121–130.
4.
EvansWE, McLeodHL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med, 2003; 348(6):538–549; doi: 10.1056/NEJMra020526
5.
VesellES. Therapeutic lessons from pharmacogenetics. Ann Intern Med, 1997; 126(8):653–655; doi: 10.7326/0003-4819-126-8-199704150-00012
WangL, McLeodHL, WeinshilboumRM. Genomics and drug response. N Engl J Med, 2011; 364(12):1144–1153; doi: 10.1056/NEJMra1010600
8.
RodenDM, McleodHL, RellingMV, et al.Pharmacogenomics. Lancet, 2019; 394(10197):521–532.
9.
MancinelliL, CroninM, SadéeW. Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci, 2000; 2(1):E4; doi: 10.1208/ps020104
10.
MorrisSA, AlsaidiAT, VerbylaA, et al.Cost effectiveness of pharmacogenetic testing for drugs with Clinical pharmacogenetics Implementation Consortium (CPIC) Guidelines: A systematic review. Clin Pharmacol Ther., 2022; 112(6):1318–1328.
11.
HicksJK, BishopJR, SangkuhlK, et al.Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther, 2015; 98(2):127–134.
12.
PatelJN, WiebeLA, DunnenbergerHM, et al.Value of supportive care pharmacogenomics in oncology practice. Oncologist, 2018; 23(8):956–964; doi: 10.1634/theoncologist.2017-0599
13.
ElliottLS, HendersonJC, NeradilekMB, et al.Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One, 2017; 12(2):e0170905; doi: 10.1371/journal.pone.0170905
Abdullah-KoolmeesH, van KeulenAM, NijenhuisM, et al.Pharmacogenetics guidelines: Overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol, 2020; 11:595219; doi: 10.3389/fphar.2020.595219
16.
TakahashiPY, RyuE, PathakJ, et al.Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. Pharmgenomics Pers Med, 2017; 10:39–47; doi: 10.2147/pgpm.s114211
17.
MilosavljevicF, BukvicN, PavlovicZ, et al.Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: A systematic review and meta-analysis: A systematic review and meta-analysis. JAMA Psychiatry, 2021; 78(3):270–280; doi: 10.1001/jamapsychiatry.2020.3643
18.
BrownLC, StantonJD, BharthiK, et al.Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective, controlled clinical trials. Clin Pharmacol Ther, 2022; 112(6):1303–1317.
19.
GredenJF, ParikhSV, RothschildAJ, et al.Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J.Psychiatr Res., 2019; 111:59–67.
20.
PérezV, SalavertA, EspadalerJ, et al.AB-GEN Collaborative Group. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial. BMC Psychiatry, 2017; 17(1):250.
21.
OslinDW, LynchKG, ShihMC, et al.PRIME Care Research Group. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME care randomized clinical trial. JAMA., 2022; 328(2):151–161.
22.
Ontario Health (Quality). Multi-gene pharmacogenomic testing that includes decision-support tools to guide medication selection for major depression: A health technology assessment. Ont Health Technol Assess Ser, 2021; 21(13):1–214.
